Agilent Technologies (A) Stock: Buy, Sell, or Hold?
A - Agilent Technologies Inc.
$146.93
3.81 (2.66%)
â˛
5d:
-2.03%
30d:
-0.88%
90d:
+13.42%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 26, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $150.86 · last confirmed Sep 9, 2026
Strength: 6.6/10
Get Alerted When A Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: A is fairly priced but lacks strong directional signals. At 2.6% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: A is fairly priced but lacks strong directional signals. At 2.6% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$186.57
Based on 6.6% avg growth
INTRINSIC VALUE TODAY
$115.84
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: A is currently trading at $146.93, which is considered fair relative to its 30-day fair value range of $144.16 to $154.57. The stock's valuation (Forward PE: 21.7) is in line with its historical norms (20.1). At these levels, the market is pricing in 2.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, A is in a strong uptrend. Immediate support is located at $141.25, while resistance sits at $156.09.
Market Sentiment: A scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $175.45 (+19.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, A is in a strong uptrend. Immediate support is located at $141.25, while resistance sits at $156.09.
Market Sentiment: A scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $175.45 (+19.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$144.16 -
$154.57
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
48.6%
Protect Your Profits
Holding A? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (18/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($175.45)
- NEUTRAL: Market pricing in 2.6% annual earnings growth - fairly valued
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$144.16 -
$154.57
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$141.25
Resistance Level
$156.10
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.72
Wall Street Target
$175.45
(+19.4%)
Revenue Growth (YoY)
8.1%
Earnings Growth (YoY)
8.5%
Profit Margin
19.5%
Valuation Premium vs History
+2.6% premium
PE vs Historical
21.7 vs 20.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.6%
(market-implied from PE analysis)
1-Year Target
$150.75
(+3%)
2-Year Target
$154.67
(+5%)
3-Year Target
$158.69
(+8%)
3-Yr Target (if PE normalizes)
(PE: 22â20)
PE COMPRESSION
$146.83
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.7, Growth: 9.1%)
$190.55
(+30%)
Base:
(SPY PE: 20.2, Growth: 9.1%)
$176.92
(+20%)
Bear:
(PE: 17.1, Growth: 9.1%)
$150.38
(+2%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (22x PE) as earnings recover.
Trailing PE: 28.57 | Current EPS (TTM): $5.01
Bull Case
$212.54
(+45%)
Analyst growth 35.0%, PE expands to 31.4
Base Case
$193.22
(+32%)
Market implied 35.0%, PE stable at 28.6
Bear Case
$97.32
(-34%)
Severe decline -20.0%, PE contracts to 24.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is A showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$638 | 51 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$229 | 49 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 49 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$338 | 47 HOLD |
Advanced A Option Strategies
Professional options setups generated by AI based on today's A price and gamma walls.
